ArticleLangenbeck's archives of surgery2026
Outcomes of patients with rectal cancer and pathological complete response as well as patients with tumor cell dedifferentiation. Two prognostic different groups of patients responding to pre-operative oncological therapy.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionMultimodal treatment represents the standard of care for rectal adenocarcinoma. A subset of patients achieves a pathological complete response (pCR), while a different subset does not. While pCR is associated with improved overall survival (OS), non-responders suffer from not being treated in a way tailored to their needs and have worse overall survival. PURPOSE: To evaluate the factors responsible for pCR and tumor cell dedifferentiation. Additionally, the prognosis of patients with pCR and tumor cell dedifferentiation and the clinical impact of dedifferentiation.
resultsThe factor responsible for pCR was clinically negative lymph node status (cN0). The incidence of dedifferentiation of tumor cells was statistically significantly higher in the group of patients who were not treated with FOLFOX/FOLFIRI chemotherapy (p = 0.033), had cN1 lymph node status (p = 0.010), and primary tumor grade 2 (p < 0.0001). The clinical impact demonstrated an association between dedifferentiation and more advanced pT (p = 0.026) and pTNM stage (p = 0.035). Parameters identified as significant negative predictors of survival were: generalization (p = 0.01, HR 1.959, 95%CI 1.171–3.276), tumor budding (p = 0.001, HR 3.391, 95%CI 1.611–7.136), perineural spread (p = 0.015, HR 2.056, 95%CI 1.150–3. 676), number of positive lymph nodes (p = 0.047, HR 1.100, 95%CI 1.001–1.210), definitive pN (pN1 p = 0.003, HR 2.008, 95%CI 1.268–3.180), and stage III and IV (p = 0.037, HR 2.050, 95%CI 1.044–4.025, p = 0.001, HR 5.482, 95%CI 2.063–14.56).
conclusionThe genetics and biological characteristics of cancer cells make rectal cancer more challenging to treat. This shows why patients need personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.